Shire Files NDA For Longer-Acting Adult ADHD Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire's NDA submission for SPD465 could allow the firm to be the first to offer a 16-hour attention deficit/hyperactivity disorder treatment
You may also be interested in...
Shire Finally Gets Resuscitated Adult ADHD Drug Back On Track With FDA
The 16-hour ADHD candidate SHP465 (SPD465) is being aimed at adults, but FDA wants a study in children, which will kick off in August and may allow a launch by the end of 2017, Shire says.
Shire Receives FDA “Approvable” Letter On Adult Adderall Product
With an adult filing for Adderall replacement Vyvanse set for mid year, the company is weighing its options, Shire told “The Pink Sheet” DAILY.
Shire Receives FDA “Approvable” Letter On Adult Adderall Product
With an adult filing for Adderall replacement Vyvanse set for mid year, the company is weighing its options, Shire told “The Pink Sheet” DAILY.